Webcast

Millie D. Long, MD, MPH, is board certified in internal medicine, preventive medicine, and gastroenterology. Dr. Long received her medical degree from University of Virginia in 2002. She then completed residency in internal medicine and a chief residency at University of Alabama at Birmingham. She completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease, all at University of North Carolina. She is currently Professor of Medicine in the Department of Medicine and Director of the Gastroenterology and Hepatology Fellowship Program at University of North Carolina at Chapel Hill.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Her research interests include prevention of complications of IBD, women’s health, and clinical epidemiology. Dr. Long has contributed to over 200 peer-reviewed publications, book chapters, and review articles and to the medical literature. She is the current co-Editor in Chief of the American Journal of Gastroenterology. She also serves as an invited reviewer for journals such as Inflammatory Bowel Diseases and Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the Board of Trustees. She is also a fellow of the American Gastroenterological Association and the Crohn’s and Colitis Foundation, where she co-chairs the Clinical Research Alliance.

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) is the Joseph B. Kirsner Professor of Medicine, a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology and Nutrition, and Director of the Inflammatory Bowel Disease (IBD) Center at the University of Chicago Medicine in Chicago, Illinois. Dr. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine in Chicago, Illinois and completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago in Chicago, Illinois, where he served as Chief Resident and Chief Fellow. He also serves as Associate Faculty at the MacLean Center for Clinical Medical Ethics, Associate Investigator at the University of Chicago Comprehensive Cancer Center, and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation, where he also serves as a Board of Trustees member. Dr. Rubin is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease. Prior to these appointments, he served as the Director of the Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Chicago for 11 years. In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn’s & Colitis Foundation’s Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He has previously served as an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis.

Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD, now in its 3^rd edition, was an associate editor of the 11th edition and is senior editor of the upcoming 12^th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. His H index is 74. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular and verified twitter feed @IBDMD with over 20,000 followers.

Dr. Adjoa Anyane-Yeboa is currently an Instructor of Medicine in the Division of Gastroenterology at Massachusetts General Hospital and Harvard Medical School. She previously completed her medical degree at the University of Cincinnati College of Medicine, her Internal Medicine Residency at the University of Illinois at Chicago where she also later served as Chief Medical Resident, and her Gastroenterology fellowship at the University of Chicago Medicine where she also served as Chief Gastroenterology Fellow. After her medical training, she went on to complete the Commonwealth Fund Fellowship in Minority Health Policy at Harvard Medical School and simultaneously received her Master’s in Public Health with a focus in health policy at the Harvard TH Chan School of Public Health. Her work is centered around healthy equity, and understanding disparities in gastrointestinal disorders such as inflammatory bowel disease and colorectal cancer, with the goal of advancing care and access for minority patients.

David Paydarfar is professor and the inaugural chair of the Department of Neurology at Dell Medical School. He previously served as professor and executive vice chair of the Department of Neurology at the University of Massachusetts Medical School, and as an associate faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. Paydarfar received a B.S. in physics (summa cum laude) from Duke University and an MD degree from The University of North Carolina at Chapel Hill. He completed his residency training in neurology at Massachusetts General Hospital and Harvard Medical School. He practices general neurology and is a fellow of the American Neurological Association and an investigator of the Clayton Foundation for Research.

Paydarfar’s clinical research program seeks to develop novel biosensors, signal-processing algorithms and user interfaces that will enable clinicians and researchers to track and predict the health of individual patients as well as entire populations. This approach will extend beyond current reactive alarm systems, enabling doctors to forecast and avert adverse disease trajectories and to test the impact of such a strategy on health outcomes. This engineering and informatics platform should provide unprecedented opportunities to conduct fieldwork on human physiology and pathophysiology.

Paydarfar’s basic research program seeks to understand mechanisms underlying disease states associated with abnormal behavior of neural oscillators such as apnea, circadian dysrhythmias and epilepsy, as well as the coordination of pacemakers with other physiological and behavioral functions. His research is funded by the National Institutes of Health, the National Science Foundation and the Clayton Foundation for Research.

Prior to joining Dell Med, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. He has served as president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP) and sits on the Scientific Advisory Board and board of directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA).

He is a member of the APA Council on Research and chairs both the APA Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments.

His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,100 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.

He has also served on the Mental Health Advisory Council of National Institute of Mental Health and the Biomedical Research Council for NASA; is co-editor in chief (with Alan F. Schatzberg, M.D.) of the Textbook of Psychopharmacology, published by the APA Press and now in its fifth edition; co-editor in chief of a new text book on Post-Traumatic Stress Disorders, and is the co-editor in chief of a new journal published by Elsevier: Personalized Medicine in Psychiatry.

He received his M.D. and Ph.D. (Neurobiology) degrees at the University of North Carolina (UNC) School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke and at Emory University before relocating to the University of Miami in 2009.

Dr. McCall has been the Case Distinguished University Chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia (MCG) at Augusta University since 2012. He also serves as Executive Vice Dean of MCG. He completed his medical degree and post-graduate psychiatric training at Duke University. He completed a Masters degree in Epidemiology from Wake Forest University. He is board certified in general psychiatry, geriatric psychiatry, and sleep medicine. His research interests include depression, electroconvulsive therapy, quality of life, insomnia, and suicide. He received 22 years of research support from the National Institute of Mental Health, and he has 500 citations, including more than 210 peer-reviewed journal articles, with an H-index of 40. He is Editor of the Journal of ECT, Past Associate Editor for the Journal of Clinical Sleep Medicine, and on the Editorial Board of Sleep. He has been the Past President of the Association for Convulsive Therapy, and a prior Director of the Board of the American Academy of Sleep Medicine. He previously was the Chair of Psychiatry and Behavioral Medicine at Wake Forest University School of Medicine from 2001-2012.

Mark S. Gold, MD, is a teacher of the year, translational researcher, author, mentor, and inventor, best known for his work on the brain systems underlying the effects of opiate drugs, cocaine, and food. He has worked as an advisor to many White House Drug Czars, White House NIDA and NIMH directors over his career of 40+ years. He is an author and inventor who has published over 1,000 peer-reviewed scientific articles, texts, and practice guidelines. This pioneering work started with detoxification studies using clonidine and lofexidine as a non-opiate detox followed by oral naltrexone at Yale in the late 70s and continued at the University of Florida (UF). Dr. Gold translated opioid studies using mouse, rat, and non-human primate models before developing his opioid withdrawal hypothesis with his Yale colleagues. He then led the first studies to demonstrate non-opioid treatment efficacy for alpha-2 agonists. He also led rapid detoxification and clonidine to naltrexone studies in the late 70s and early 80s. Dr. Gold, trying to find patients who would take oral naltrexone, began his studies of Impaired Health Professionals and employees in health and safety occupations.

Dr. Gold has received a number of national awards for his research, including the Lifetime Achievement Award of the National Association of Addiction Treatment Professionals, Foundations Fund Prize (APA), PRIDE Lifetime Achievement Award, DEA 30 Years of Service Pin, the McGovern Award for Lifetime Achievement (ASAM-ABAM 2015), National Leadership Award (NAATP), DARE Lifetime Achievement Award, Public Relations Society’s Silver Anvil Award, and China Academy of Sciences and DARE awards for his career in research and prevention (2015). More recently, he received the PATH Foundations Lifetime Achievement Award (2016) as one of the “fathers” of addiction medicine, presented to him by President Obama’s White House Drug Czar Michael Botticelli. Dr. Gold was awarded Distinguished Alumni Awards at Yale University, University of Florida, and Washington University in St. Louis as well as the Wall of Fame at the UF College of Medicine.

Dr. Gold was a Professor, Eminent Scholar, Distinguished Professor, Distinguished Alumni Professor, Chairman, and Emeritus Eminent Scholar during his 25 years at the University of Florida. His work is widely cited by his peers. It includes citation classics in cocaine neurobiology, opioid addiction neurobiology and treatment, and food and process addictions. He proved that cocaine was misclassified as safe, or the champagne of drugs, leading to revision in the DSM 3 and diagnosis of addiction. He has been called a groundbreaking researcher, father of medication-assisted recovery, the first to translate rat experiments into theory and treatments for human addicts, and mentor of the next generation of addiction researchers and clinicians. Working closely with Bart Hoebel at Princeton University, Dr. Gold helped develop the food addiction theory he posited in the 80s. With Nicole Avena, he worked on sugar self-administration models for hedonic overeating and developed new treatments for overeating and obesity. Kelly Brownell and Dr. Gold’s Food and Addiction, published by Oxford University Press, has been widely recognized as groundbreaking. Although working on food and drug-like reinforcement systems has been an important part of his work for 30 years, he has also worked on dual disorders, anorexia and bulimia nervosa. Dr. Gold worked closely with Al Rhoton and Bill Luttge to establish the UF Brain Institute. He was an original member of the McKnight Brain Institute and Director working to develop programs in Psychiatry, Addiction, Neurology, and Neurosurgery.

Since his retirement as a Director of the McKnight Brain Institute, Chairman, Distinguished Professor, and a full-time academic in 2014, Dr. Gold has continued his teaching, mentoring, research, and writing. He finished his 5-year State Department grant on opium smokers and the effects of second- and third-hand opium on children in Afghanistan. He has worked on de novo clinical addiction programs at the Medical College of Georgia, Northwestern, UF, and Tulane Lakeview Health. Dr. Gold regularly lectures at national and international meetings, medical societies, grand rounds around the United States, and international and national scientific meetings on his career, bench-to-bedside science in eating disorders, obesity, and addictions. Recently, he gave a keynote speech at the National Opioid Summit and Florida Opioid Summit as well as for the DEA-DOJ. He speaks regularly at medical schools across the United States, recently at Yale University, Mayo Clinic, Tulane, Washington University in St. Louis, Stanford, University of Connecticut (UConn), UCSF, Emory, Harvard-McLean-Borden Cottage, and UNC. He has given recent keynote addresses at American College of Psychiatrists, CADCA, ASAM, NAATP, APA, and Biological Psychiatry as well as a many states, medical, and psychiatric associations, dealing with the opioid epidemic.

Dr. Gold is an Adjunct Professor in the Department of Psychiatry at Washington University and an active member of the Clinical Council at the Washington University School of Medicine’s Public Health Institute. He has Wash University mentees and works with them regularly. He is the Director of Research for the DEA Educational Association, working closely with DEA and moderating their quarterly educational events broadcast from DEA Headquarters around the world.

Dr. Chey received a medical degree and training in internal medicine at Emory University School of Medicine. He completed a fellowship in gastroenterology and has remained as faculty at the University of Michigan in Ann Arbor where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology. He holds a joint appointment in the Department of Nutrition Sciences.

Dr. Chey’s research interests focus on the diagnosis and treatment of functional bowel disorders and H. pylori infection. He has mentored more than 50 students, residents, fellows, and junior faculty, many of which are leaders in gastroenterology. He is a medical innovator and holds several patents. Dr. Chey is former Co-Editor-in-Chief of the American Journal of Gastroenterology and has authored more than 350 manuscripts, reviews, chapters, and books. He is a member of the Board of Trustees of the American College of Gastroenterology, Board of Directors of the Rome Foundation, Council of the American Neurogastroenterology and Motility Society, and Board of Directors of the International Foundation of Functional Gastrointestinal Disorders.

Dr. Chey has been elected to “Best Doctors” since 2001 and received the Dean’s Outstanding Clinician Award and Dean’s Award for Innovation and Commercialization at the University of Michigan. He has also received the Distinguished Clinician Award from the American Gastroenterological Association. In 2020 he was awarded honorary membership to the Academy of Nutrition and Dietetics and the prestigious Berk/Fise Award from the American College of Gastroenterology.

Anthony J. Lembo, MD, is a Professor of Medicine at Harvard Medical School. He also serves as the Director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center (BIDMC) Division of Gastroenterology in Boston, MA. Dr. Lembo earned his undergraduate degree in mathematics at Amherst College in Amherst, MA and then received his MD from Tufts Medical School in Boston, MA. He subsequently completed his internal medicine internship/residency as well as gastroenterology fellowship at UCLA Medical Center in Los Angeles, CA. Dr. Lembo subsequently became a Clinical Instructor of Medicine at UCLA in 1996 and served as the co-Director of the Functional Bowel Disorder (FBD) and Gastrointestinal (GI) Motility Center at UCLA Medical Center. While at UCLA he conducted research in FBDs. In 1997 he joined the faculty at BIDMC in Boston MA. Dr. Lembo is currently the Director of the GI Motility and Functional Bowel Disorder Center at the BIDMC and Co-Director of the GI Motility Laboratory. He is an Associate Editor of Journal of Clinical Gastroenterology and Digestive Diseases and Science. His research has focused on the developed of novel treatments for FBDs including chronic idiopathic constipation. Dr. Lembo’s research interest has also explored the role of placebo and methods of enhancing the placebo response.

Dr. Drossman received his MD degree at Albert Einstein College of Medicine and subspecialized in biopsychosocial (psychosomatic) medicine and gastroenterology. He is a Fellow of the American College of Physicians, a Master of the American College of Gastroenterology, Past-President of the American Psychosomatic Society (1997), and Founder and President of the Rome Foundation (for 29 years).

Dr. Drossman has founded multiple organizations to advance patient-centered education and treatment of disorders of gut-brain interaction (DGBIs). He founded the Rome Foundation, a non-profit whose mission is to improve the lives of individuals with DGBIs. He served as its President from its inception until May 2019 (www.theromefoundation.org), and is currently its President Emeritus and Chief of Operations. Dr. Drossman has served as Senior Editor of the textbooks Functional Gastrointestinal Disorders Rome I, II, III, and IV as well as other Rome IV products released since 2016: Multi-Dimensional Clinical Profile for Functional Gastrointestinal Disorders (completing 2nd edition), Rome IV Clinical Algorithms (2nd edition), Rome IV Slide Sets, and Rome IV GI Genius (an intelligent software application). In his gastroenterology practice, he receives referrals nationally to consult or manage the care of difficult-to-diagnose and -treat patients with functional gastrointestinal and motility disorders.

As Founder and President of DrossmanCare (Center for Education and Practice of Biopsychosocial Care) Dr. Drossman produces educational materials to teach patient-centered care for patients with DGBIs. He has produced peer-reviewed articles and videotapes on medical interviewing and the patient-doctor relationship. Dr. Drossman also facilitates workshops and communication skills training programs and has received numerous awards, both as an educator and practitioner. Most recently, he has been collaborating with the Rome Foundation to produce a curriculum for training clinicians that includes the Communication 101 and 202 video series, Train the Trainer programs, and workshops and symposia globally.

Dr. Drossman has written over 500 articles and book chapters, serves on six editorial and advisory boards, was Associate Editor of the journal Gastroenterology, and was the Gastroenterology Section Editor of the Merck Manual (for 17 years).

His research relates to the clinical, epidemiological, psychosocial, and treatment aspects of gastrointestinal disorders, and he has been principal investigator in several federally funded epidemiological, outcomes, and abuse grants, including brain imaging in irritable bowel syndrome.